IRulya Therapeutics Inc. IRLA
IRulya Therapeutics Inc. (Nasdaq: IRLA) is a respiratory drug developer. Its lead program, LAM-001, is in Phase 2 for Pulmonary hypertension associated with ILD (PH-ILD); bronchiolitis obliterans syndrome. Its next catalyst on record is LAM-001: Phase 2 BOS trial results (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LAM-001 — Phase 2 BOS trial results (Q1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LAM-001 (inhaled dry powder rapamycin) | PH-ILD | small molecule | Phase 2b data 2028-Q1 |
| LAM-001 | Bronchiolitis obliterans syndrome (post lung transplant) | small molecule | Phase 2 results 2027-Q1 |
| LAM-001 | Sarcoidosis-associated pulmonary hypertension | small molecule | Phase 2 start late 2026; data 2028-Q4 |
Recent results and decisions
- Oct 9, 2026started Company recently initiated the Phase 2b trial of LAM-001 in PH-ILD; data anticipated Q1 2028.
The Company recently initiated a Phase 2b trial in PH-ILD, and data are anticipated in the first quarter of 2028.
Filing - May 18, 2026positive Open-label Phase 2a (n=10; 6 evaluable): PH-ILD subgroup (n=4) 6MWD +67.4 m and PVR -33.9% at 24 weeks; well tolerated, no drug-related SAEs.
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeks
Filing - Jan 29, 2026missed Phase 3 NEAT missed primary endpoint (RmICARS change 0.94 vs 2.24, difference -1.30, p=0.0851) and key secondary CGI-S (p=0.522); company ceasing eDSP development.
The primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo, did not reach statistical significance.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.